Gracell Biotechnologies Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Gracell Biotechnologies Inc (GRCL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Gracell Biotechnologies Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Gracell Biotechnologies Inc | - | - | - | - |
| High-Confidence Competitors (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GRCL Stock Performance relative to its Competitors
GRCL Stock Performance relative to High-Confidence Competitors
Gracell Biotechnologies Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Celyad Oncology AG | Named by the company | 85% |
| Novartis AG | Named by the company | 85% |
| bluebird Bio, Inc. | Named by the company | 85% |
| Kite Pharma, Inc. | Named by the company | 85% |
| Gilead Sciences, Inc. | Named by the company | 85% |
| Poseida Therapeutics, Inc. | Named by the company | 85% |
| Celgene Corporation | Named by the company | 85% |
| Nanjing Legend Biotech | Named by the company | 85% |
| Allogene, Inc. | Named by the company | 85% |
| Juno Therapeutics, Inc. | Named by the company | 85% |
| Legend Biotech Corporation | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Gracell Biotechnologies Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.